Literature DB >> 15194172

Primary pulmonary arterial hypertension: a look back.

Alfred P Fishman1.   

Abstract

For the first half of the twentieth century, the published reports on primary pulmonary hypertension (PPH) were confined to clinical pathological correlations. In the 1950s the physiological aspects began to be reported followed by epidemiologic studies triggered by an epidemic of PPH due to the ingestion of an appetite suppressant, aminorex fumarate. The epidemic prompted a series of meetings of the World Health Organization, which led, in turn, to the creation of the U.S. Registry of Primary Pulmonary Hypertension, standardization of nomenclature, and an etiologic classification of all types of pulmonary hypertension.

Entities:  

Mesh:

Year:  2004        PMID: 15194172     DOI: 10.1016/j.jacc.2004.03.019

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Stimulants and Pulmonary Arterial Hypertension: An Update.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Adv Pulm Hypertens       Date:  2018

2.  Giant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural course.

Authors:  Anton Smalcelj; Vojtjeh Brida; Miroslav Samarzija; Ante Matana; Eduard Margetic; Niksa Drinkovic
Journal:  Tex Heart Inst J       Date:  2005

3.  Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.

Authors:  Sat Sharma; Tarek Kashour; Roger Philipp
Journal:  Tex Heart Inst J       Date:  2005

4.  Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study.

Authors:  Wan-Jing Ho; Chia-Pin Lin; Chun-Li Wang; Lung-An Hsu; Kuang-Hui Yu; Shue-Fen Luo; Ji-Yih Chen; Tsu-Shiu Hsu
Journal:  Acta Cardiol Sin       Date:  2014-05       Impact factor: 2.672

Review 5.  DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Authors:  Julian Maier; Felix P Mayer; Simon D Brandt; Harald H Sitte
Journal:  ACS Chem Neurosci       Date:  2018-10-05       Impact factor: 5.780

6.  Progress in the understanding and management of pulmonary arterial hypertension.

Authors:  A M Chakrabarti; J A Mitchell; S J Wort
Journal:  Glob Cardiol Sci Pract       Date:  2015-04-04

7.  Implication of overexpression of dishevelled-associated activator of morphogenesis 1 (Daam-1) for the pathogenesis of human Idiopathic Pulmonary Arterial Hypertension (IPAH).

Authors:  Shun Yanai; Megumi Wakayama; Haruo Nakayama; Minoru Shinozaki; Hisayuki Tsukuma; Naobumi Tochigi; Tetsuo Nemoto; Tsutomu Saji; Kazutoshi Shibuya
Journal:  Diagn Pathol       Date:  2017-03-14       Impact factor: 2.644

8.  Oxidative profiling of the failing right heart in rats with pulmonary hypertension.

Authors:  Xinhong Wang; Nataliia V Shults; Yuichiro J Suzuki
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

9.  Pulmonary hypertension: more to be done.

Authors:  Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

10.  Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study.

Authors:  Hale Karapolat; Müyesser Ece Çınar; Göksel Tanıgör; Sanem Nalbantgil; Meral Kayıkçıoğlu; Nesrin Moğulkoç; Hakan Kültürsay
Journal:  Turk J Phys Med Rehabil       Date:  2019-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.